MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients

Abstract Purpose The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DL...

Full description

Bibliographic Details
Main Authors:	Yanjie Wang, Donglin Liu, Xudong Zhang, Mingzhi Zhang, Shenglei Li, Xiaoyan Feng, Meng Dong, Shanshan Ma, Siyu Qian, Zeyuan Wang, Yue Zhang, Pengyuan Wang, Shuhao Mei, Qingjiang Chen
Format:	Article
Language:	English
Published:	Wiley 2023-09-01
Series:	Cancer Medicine
Subjects:	diffuse large B‐cell lymphoma bulky mass immunohistochemistry lymphoma MYC radiotherapy
Online Access:	https://doi.org/10.1002/cam4.6463

Similar Items

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
by: Julum Nwanze, et al.
Published: (2017-09-01)

Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma
by: Aydan KILIÇARSLAN, et al.
Published: (2018-09-01)

MYC’s Fine Line Between B Cell Development and Malignancy
by: Oriol de Barrios, et al.
Published: (2020-02-01)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements, Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Rearrangement, and Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Cluster Amplification
by: Masashi Miyaoka, et al.
Published: (2022-11-01)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
by: Socorro María Rodríguez‐Pinilla, et al.
Published: (2022-02-01)

Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
by: Giulio Donati, et al.
Published: (2023-06-01)

A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma
by: Jayalakshmi Balakrishna, et al.
Published: (2022-01-01)

High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
by: Cheng-Chih Tsai, et al.
Published: (2021-03-01)

Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation
by: Ekaterina Mikhailovna Stasevich, et al.
Published: (2022-04-01)

Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma
by: René Winkler, et al.
Published: (2022-12-01)

The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
by: Jisun Hwang, et al.
Published: (2021-07-01)

Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques
by: Elisabetta Maria Abenavoli, et al.
Published: (2023-03-01)

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning
by: Thomas E. Tavolara, et al.
Published: (2024-01-01)

Alternative <i>c-MYC</i> mRNA Transcripts as an Additional Tool for c-Myc2 and c-MycS Production in BL60 Tumors
by: Dina Ibrahim, et al.
Published: (2022-06-01)

Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort
by: Bogyeong Han, et al.
Published: (2020-11-01)

Clinicopathological analysis of DLBCL/HGBL with MYC, BCL2 and BCL6 gene rearrangement
by: WEI Jing, HE Yaqi, XUE Tian, BAI Qianming, SHUI Ruohong, LU Hongfen, LI Xiaoqiu, YU Baohua
Published: (2023-09-01)

Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition
by: Candace J. Poole, et al.
Published: (2018-11-01)

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
by: A. Vera de Jonge, et al.
Published: (2020-10-01)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
by: Man Zhang, et al.
Published: (2023-05-01)

Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment
by: Said Izreig, et al.
Published: (2020-05-01)

The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas
by: Mutaz Jamal Al-Khreisat, et al.
Published: (2022-06-01)

Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
by: R. K. Karakulov, et al.
Published: (2022-01-01)

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma
by: Xiaohu Huang, et al.
Published: (2021-02-01)

Serine Biosynthesis Pathway Supports MYC–miR-494–EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells
by: Emilia Białopiotrowicz, et al.
Published: (2020-03-01)

Germinal Centre B Cell Functions and Lymphomagenesis: Circuits Involving MYC and MicroRNAs
by: Marcela Cristina Robaina, et al.
Published: (2019-10-01)

MYC function and regulation in physiological perspective
by: Rajiv Kumar Jha, et al.
Published: (2023-10-01)

Differential Transcriptional Reprogramming by Wild Type and Lymphoma-Associated Mutant MYC Proteins as B-Cells Convert to a Lymphoma Phenotype
by: Amir Mahani, et al.
Published: (2021-12-01)

Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
by: Chuquan Shang, et al.
Published: (2023-09-01)

The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma
by: Marion Lacroix, et al.
Published: (2023-03-01)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
by: Vanja Zeremski, et al.
Published: (2023-07-01)

Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma
by: Yi Gong, et al.
Published: (2017-06-01)

Review: proteins c-Myc and Myc-nick as potential targets for the melignant melanoma treatment
by: G. Maryniuk, et al.
Published: (2023-07-01)

Clinical significance of MYC family protein expression in surgically resected high‐grade neuroendocrine carcinoma of the lung
by: Yuki Oshima, et al.
Published: (2023-03-01)

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
by: Meng-Ke Liu, et al.
Published: (2022-10-01)

The Molecular ‘Myc-anisms’ behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics
by: Jessica McAnulty, et al.
Published: (2020-12-01)

Oncological Adequacy of Laparoscopic Surgery for Bulky Gastric Cancer: Results of a Western Single-Center Series
by: Edoardo Maria Muttillo, et al.
Published: (2023-11-01)

The Myc Road to Hearing Restoration
by: Bernd Fritzsch, et al.
Published: (2012-09-01)

Gene Transactivation and Transrepression in MYC-Driven Cancers
by: Marika Scafuro, et al.
Published: (2021-03-01)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
by: Susanna Tokola, et al.
Published: (2020-03-01)

IBtkα Activates the β-Catenin-Dependent Transcription of <i>MYC</i> through Ubiquitylation and Proteasomal Degradation of GSK3β in Cancerous B Cells
by: Eleonora Vecchio, et al.
Published: (2022-02-01)